PTGS2 and malignant colon neoplasm: After receiving treatment with COX-2 inhibitors that selectively inhibit COX-2 or non-selectively inhibit COX-2 expression with nonsteroidal anti-inflammatory drugs (NSAIDs), several studies have shown a decreased risk for breast, lung, prostate, and colon cancers [1,9].